Solid forms of [4-(3-fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone

Solid forms of [4-(3-fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone

The present invention relates to four distinct crystalline forms and to an amorphous form of [4-(3-Fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone, and to their use in the preparation of pharmaceutical compositions....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Bubendorf, Andre, Deynet-Vucenovic, Annette, Diodone, Ralph, Grassmann, Olaf, Lindenstruth, Kai, Pinard, Emmanuel, Rohrer, Franziska E, Schwitter, Urs
Format: Patent
Sprache:eng
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator Bubendorf, Andre
Deynet-Vucenovic, Annette
Diodone, Ralph
Grassmann, Olaf
Lindenstruth, Kai
Pinard, Emmanuel
Rohrer, Franziska E
Schwitter, Urs
description The present invention relates to four distinct crystalline forms and to an amorphous form of [4-(3-Fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone, and to their use in the preparation of pharmaceutical compositions. The compounds of present invention are suitable for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.
format Patent
fullrecord <record><control><sourceid>uspatents_EFH</sourceid><recordid>TN_cdi_uspatents_grants_08039473</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>08039473</sourcerecordid><originalsourceid>FETCH-uspatents_grants_080394733</originalsourceid><addsrcrecordid>eNqNjM0KwjAQhHvxIOo75NiCC7U_qGdRvNdbEQmY2ECaDUkKxhfxdd1iwass7Ows38w8eTeo1Z1JdL1nKFlbQVqC1AM6hBqCU9-7F6GLGmx06q4MFBB1BlZZ4fiL_IY8tDWMGDfCD1qioVcBadpkUKxpfmWET3208RmpqROEX6c8GrFMZpJrL1aTLhJ2Ol4OZxi85UGY4G8Px0fJd3m5r7Zl-QfyAXleT8g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Solid forms of [4-(3-fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone</title><source>USPTO Issued Patents</source><creator>Bubendorf, Andre ; Deynet-Vucenovic, Annette ; Diodone, Ralph ; Grassmann, Olaf ; Lindenstruth, Kai ; Pinard, Emmanuel ; Rohrer, Franziska E ; Schwitter, Urs</creator><creatorcontrib>Bubendorf, Andre ; Deynet-Vucenovic, Annette ; Diodone, Ralph ; Grassmann, Olaf ; Lindenstruth, Kai ; Pinard, Emmanuel ; Rohrer, Franziska E ; Schwitter, Urs ; Hoffmann-La Roche Inc</creatorcontrib><description>The present invention relates to four distinct crystalline forms and to an amorphous form of [4-(3-Fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone, and to their use in the preparation of pharmaceutical compositions. The compounds of present invention are suitable for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.</description><language>eng</language><creationdate>2011</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8039473$$EPDF$$P50$$Guspatents$$Hfree_for_read</linktopdf><link.rule.ids>230,308,780,802,885,64039</link.rule.ids><linktorsrc>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8039473$$EView_record_in_USPTO$$FView_record_in_$$GUSPTO$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Bubendorf, Andre</creatorcontrib><creatorcontrib>Deynet-Vucenovic, Annette</creatorcontrib><creatorcontrib>Diodone, Ralph</creatorcontrib><creatorcontrib>Grassmann, Olaf</creatorcontrib><creatorcontrib>Lindenstruth, Kai</creatorcontrib><creatorcontrib>Pinard, Emmanuel</creatorcontrib><creatorcontrib>Rohrer, Franziska E</creatorcontrib><creatorcontrib>Schwitter, Urs</creatorcontrib><creatorcontrib>Hoffmann-La Roche Inc</creatorcontrib><title>Solid forms of [4-(3-fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone</title><description>The present invention relates to four distinct crystalline forms and to an amorphous form of [4-(3-Fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone, and to their use in the preparation of pharmaceutical compositions. The compounds of present invention are suitable for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.</description><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2011</creationdate><recordtype>patent</recordtype><sourceid>EFH</sourceid><recordid>eNqNjM0KwjAQhHvxIOo75NiCC7U_qGdRvNdbEQmY2ECaDUkKxhfxdd1iwass7Ows38w8eTeo1Z1JdL1nKFlbQVqC1AM6hBqCU9-7F6GLGmx06q4MFBB1BlZZ4fiL_IY8tDWMGDfCD1qioVcBadpkUKxpfmWET3208RmpqROEX6c8GrFMZpJrL1aTLhJ2Ol4OZxi85UGY4G8Px0fJd3m5r7Zl-QfyAXleT8g</recordid><startdate>20111018</startdate><enddate>20111018</enddate><creator>Bubendorf, Andre</creator><creator>Deynet-Vucenovic, Annette</creator><creator>Diodone, Ralph</creator><creator>Grassmann, Olaf</creator><creator>Lindenstruth, Kai</creator><creator>Pinard, Emmanuel</creator><creator>Rohrer, Franziska E</creator><creator>Schwitter, Urs</creator><scope>EFH</scope></search><sort><creationdate>20111018</creationdate><title>Solid forms of [4-(3-fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone</title><author>Bubendorf, Andre ; Deynet-Vucenovic, Annette ; Diodone, Ralph ; Grassmann, Olaf ; Lindenstruth, Kai ; Pinard, Emmanuel ; Rohrer, Franziska E ; Schwitter, Urs</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-uspatents_grants_080394733</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2011</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Bubendorf, Andre</creatorcontrib><creatorcontrib>Deynet-Vucenovic, Annette</creatorcontrib><creatorcontrib>Diodone, Ralph</creatorcontrib><creatorcontrib>Grassmann, Olaf</creatorcontrib><creatorcontrib>Lindenstruth, Kai</creatorcontrib><creatorcontrib>Pinard, Emmanuel</creatorcontrib><creatorcontrib>Rohrer, Franziska E</creatorcontrib><creatorcontrib>Schwitter, Urs</creatorcontrib><creatorcontrib>Hoffmann-La Roche Inc</creatorcontrib><collection>USPTO Issued Patents</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Bubendorf, Andre</au><au>Deynet-Vucenovic, Annette</au><au>Diodone, Ralph</au><au>Grassmann, Olaf</au><au>Lindenstruth, Kai</au><au>Pinard, Emmanuel</au><au>Rohrer, Franziska E</au><au>Schwitter, Urs</au><aucorp>Hoffmann-La Roche Inc</aucorp><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Solid forms of [4-(3-fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone</title><date>2011-10-18</date><risdate>2011</risdate><abstract>The present invention relates to four distinct crystalline forms and to an amorphous form of [4-(3-Fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone, and to their use in the preparation of pharmaceutical compositions. The compounds of present invention are suitable for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_uspatents_grants_08039473
source USPTO Issued Patents
title Solid forms of [4-(3-fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T04%3A16%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-uspatents_EFH&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Bubendorf,%20Andre&rft.aucorp=Hoffmann-La%20Roche%20Inc&rft.date=2011-10-18&rft_id=info:doi/&rft_dat=%3Cuspatents_EFH%3E08039473%3C/uspatents_EFH%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true